Eveliqure Biotechnologies is an Austrian biotech company that is the game-changer amongst vaccine companies, championing novel technologies to make the world safe from diarrhoea. Eveliqure is passionate about improving the quality of life for both the poor and the privileged by providing innovative medical solutions that fight diseases of all walks of life. Eveliqure has generated a strong pre-clinical data package that justifies testing ShigETEC in humans and has initiated manufacturing and regulatory activities to ensure timely progress and readiness for the scope of this grant application. EVQ has been granted patents on ShigETEC in major territories (including EU and US), secured sufficient private investment and recruited experienced biotech entrepreneurs and vaccine development experts to ensure the maximum exploitation of the results anticipated in this proposal. The complementary and parallel efforts of introducing ShigETEC for travellers to endemic regions greatly supports the advancement of the vaccine for the endemic paediatric population.